Latest Breaking News On - Kempen co - Page 18 : comparemela.com
Investegate |Tritax EuroBox PLC Announcements | Tritax EuroBox PLC: Result of Issue
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Tritax EuroBox PLC Announcements | Tritax EuroBox PLC: Proposed Equity Issue
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Tritax EuroBox PLC Announcements | Tritax EuroBox PLC: Publication of Prospectus
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Y-mAbs Announces Pricing of Public Offering of Common Stock
February 17, 2021 19:14 ET | Source: Y-mAbs Therapeutics, Inc Y-mAbs Therapeutics, Inc New York, UNITED STATES
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its public offering of 2,439,025 shares of its common stock at a public offering price of $41.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100.0 million. All of the shares are being offered by Y-mAbs. In addition, Y-mAbs has granted the underwriters a 30-day option to purchase up to an additional 365,853 shares of com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Autolus Announces Pricing of Public Offering
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 14,285,715 American Depositary Shares ( ADSs ) representing 14,285,715 ordinary shares at a public offering price of $7.00 per ADS, for total gross proceeds of app